Compare Biogen Inc (BIIB) vs Fox Corp Class B (FOX) Price & Performance

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

FOX trades at $50.22, up 3.02% with bullish technical signals and strong earnings beats. Recent Q1 2026 EPS of $1.32 exceeded expectations by 33.6%, continuing a pattern of outperformance. The company shows improved cash flow with 2025 operating cash flow reaching $3.32 billion, while revenue grew to $16.30 billion. Technical indicators show mixed signals with RSI at neutral levels but ADX suggesting strong trend momentum.

The outlook remains positive with analyst price targets suggesting 27-39% upside potential. Key risks include competitive pressures in streaming and potential volatility from the recent Roku acquisition. Wall Street sentiment is cautiously optimistic with 43% buy ratings, though the stock faces near-term execution challenges with projected 2026 cash flow turning negative.